Clinical trial NCT04565834: Effect of Genetic Alterations Affecting the Genes Encoding the Major Enzymes of the Kynurenine Pathway on Suicidal Behavior
Official title: Étude Des Altérations Génétiques (polymorphismes) Des Gènes-clés De La Voie Kynurénine Sur Le Comportement Suicidaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tryptophan Metabolism Alterations
Polymorphism
Suicidal Behavior
Keywords: sucidal behavior
Inflammation
Kynurenines
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
Collaborators: name: Universidad Autonoma de Madrid
First posted: 2020-09-25
Enrollment: 849
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients for whom biological samples have been collected and registered in the hospital's databank for the purpose of previously registered studies : SPAD (RCB no. 2016-A01375-46), SMART-CRISIS (RCB no.: 2017-A02634-49) and SUI-PREDICT (RCB no.: 2016-A00845-46) and several studies conducted at the university hospitals of Puerta de Hierro, Ramon y Cajal et Fundacion Jiminez Diaz in Madrid, Spain, since 2004.

Brief summary: Current research has shown that an imbalance in the Kynurenine pathway plays a role in the physiopathology of neurogenerative and mental disorders (with a decrease in neuroprotective metabolites and an increase in neurotoxic products). So far the research has concentrated on the enzymes IDO 1/2, KAT (1-4), KMO and ACMSD which are the key players in this pathway. Several polymorphisms affecting these enzymes have been associated with certain disorders characterized by a deregulation of the inflammation and immune response (McCauley et al 2009,Tardito et al 2013, Lee et al 2014), but the link between these enzymes and suicidal behavior is not yet clear. The investigators hypothesize that people with history of suicide attempt would have a genetic alterations of the kynurenine pathway specific for suicidal behavior.


Eligibility criteria: Inclusion Criteria:

* For the "Sucide attempters" group: Any patient aged 18 or over who has made at least one suicide attempt.
* For the two control groups: Any patient aged 18 or over, suffering from depression but has never attempted to commit suicide and any healthy subject who has never had any mental disorders.

Exclusion Criteria:

* Any patient who has expressed opposition to the use of his/her data.

Primary outcomes:
measure: The genotypic and allelelic frequencies of IDO1 rs7820268 SNP in each studied group
timeFrame: 24 months
measure: The genotypic and allelelic frequencies of IDO2 rs10109853 SNP in each studied group
timeFrame: 24 months
measure: The genotypic and allelelic frequencies of KMO rs1053230 SNP in each studied group
timeFrame: 24 months
measure: The genotypic and allelelic frequencies of KAT1 rs10988134 SNP in each studied group
timeFrame: 24 months
measure: The genotypic and allelelic frequencies of ACMSD rs2121337 SNP in each studied group
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
measure: Age of subjects
timeFrame: 24 months
measure: Gender of subjects
timeFrame: 24 months
measure: Marital status of subjects
timeFrame: 24 months
measure: Education level of subjects
timeFrame: 24 months
measure: Diagnosis
timeFrame: 24 months
measure: Number of suicide attempts
timeFrame: 24 months
measure: Age of first suicide attempt
timeFrame: 24 months
Locations:
city: Nîmes
country: France
facility: Department of Psychiatry, Nimes University Hospital
state: Gard
city: Madrid
country: Spain
facility: José-Fernandez-Piqueras
Study officials:
References: